Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT005
MIFTS: 52

Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Diabetes Insipidus

About this section

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 76 29 6 43 44 15 73

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases Nephrological diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9409
ICD10 33 E23.2
ICD9CM 35 253.5
MeSH 44 D003919
NCIt 50 C43263
SNOMED-CT 68 15771004
UMLS 73 C0011848
Sources

Summaries for Diabetes Insipidus

About this section
MedlinePlus : 43 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to diabetes insipidus, nephrogenic, x-linked and diabetes insipidus, nephrogenic, autosomal. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and Glucose / Energy Metabolism. The drugs Tolvaptan and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Sources

Related Diseases for Diabetes Insipidus

About this section

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 34.6 AQP2 AVPR2
2 diabetes insipidus, nephrogenic, autosomal 34.3 AQP2 ARHGAP4 AVP AVPR2 CLCNKA SLC12A1
3 diabetes insipidus, neurohypophyseal 34.1 AQP2 AVP AVPR2 POMC PRL
4 wolfram syndrome 1 33.6 AVP WFS1
5 wolfram syndrome 33.5 AVP CISD2 WFS1
6 wolfram syndrome 2 32.2 CISD2 WFS1
7 syndrome of inappropriate antidiuretic hormone 30.3 AQP2 AVP AVPR2 POMC
8 hypopituitarism 30.2 CRH INS POMC PRL
9 empty sella syndrome 30.1 POMC PRL
10 nephrogenic syndrome of inappropriate antidiuresis 30.0 AVP AVPR2
11 bartter disease 30.0 CLCNKA REN SLC12A1
12 pituitary apoplexy 30.0 INS POMC PRL
13 hypoadrenalism 29.9 CRH POMC
14 amenorrhea 29.8 CRH POMC PRL
15 lung oat cell carcinoma 29.8 AVP POMC
16 polycystic kidney disease 29.8 AQP2 AVPR2 REN
17 idiopathic edema 29.8 AQP2 INS
18 burns 29.7 CRH INS
19 hypoaldosteronism 29.7 POMC REN
20 pituitary hormone deficiency, combined, 2 29.6 AVP POMC PRL
21 inappropriate adh syndrome 29.5 AQP2 AVP AVPR2 POMC REN
22 pituitary infarct 29.5 POMC PRL
23 adenohypophysitis 29.5 POMC PRL
24 hypothalamic disease 29.5 CRH POMC PRL
25 acromegaly 29.5 INS POMC PRL
26 hypokalemia 29.4 AQP2 POMC REN SLC12A1
27 chromophobe adenoma 29.3 AVP INS POMC PRL
28 sheehan syndrome 29.3 CRH INS POMC PRL
29 anorexia nervosa 29.2 CRH POMC PRL
30 conn's syndrome 29.2 CRH POMC PRL REN
31 pituitary gland disease 29.0 AVP CRH INS POMC PRL
32 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.5
33 hereditary central diabetes insipidus 12.5
34 acquired central diabetes insipidus 12.5
35 gestational diabetes insipidus 12.4
36 dipsogenic diabetes insipidus 12.4
37 hypopituitarism, congenital, with central diabetes insipidus 12.2
38 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 12.2
39 langerhans cell histiocytosis 11.6
40 erdheim-chester disease 11.5
41 wolfram syndrome, mitochondrial form 11.2
42 hyperostosis frontalis interna 11.1
43 polyhydramnios, megalencephaly, and symptomatic epilepsy 11.1
44 wolfram-like syndrome, autosomal dominant 11.1
45 culler-jones syndrome 11.1
46 hashimoto-pritzker syndrome 11.1
47 histiocytosis 10.6
48 diabetes mellitus 10.6
49 3-methylglutaconic aciduria, type iii 10.5
50 lymphocytic hypophysitis 10.4

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus
Sources

Symptoms & Phenotypes for Diabetes Insipidus

About this section

MGI Mouse Phenotypes related to Diabetes Insipidus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 AQP2 AVP AVPR2 CISD2 CRH INS
2 homeostasis/metabolism MP:0005376 10.03 AQP2 AVP AVPR2 CISD2 CLCNKA CRH
3 growth/size/body region MP:0005378 10.02 AQP2 AVPR2 CISD2 CLCNKA CRH INS
4 integument MP:0010771 9.81 AQP2 AVPR2 CISD2 CRH INS POMC
5 mortality/aging MP:0010768 9.65 AQP2 AVP AVPR2 CISD2 CLCNKA INS
6 renal/urinary system MP:0005367 9.32 AQP2 AVP AVPR2 CISD2 CLCNKA CRH
Sources

Drugs & Therapeutics for Diabetes Insipidus

About this section

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 371)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150683-30-0 216237
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-23-7 5754
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-03-3
5
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
7
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 210101-16-9 151171
8
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
9
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-31-9 3440
10
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
11
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 28523-86-6 5206
12
Misoprostol Approved Phase 4 59122-46-2 5282381
13
Phenylephrine Approved Phase 4,Phase 2,Not Applicable 59-42-7 6041
14
Oxymetazoline Approved, Investigational Phase 4,Phase 2,Not Applicable 1491-59-4 4636
15
Ephedrine Approved Phase 4,Phase 2,Not Applicable 299-42-3 9294
16
Pseudoephedrine Approved Phase 4,Phase 2,Not Applicable 90-82-4 7028
17
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
18
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
20
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
23 tannic acid Approved Phase 4,Phase 2,Not Applicable
24
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
27
Synephrine Experimental Phase 4 1994-07-5, 94-07-5 7172
28 arginine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Deamino Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Vasopressins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hydrocortisone-17-butyrate Phase 4,Phase 3
41 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Hypnotics and Sedatives Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
48 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
49 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 463)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population Unknown status NCT02584231 Phase 4 desmopressin
2 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4 Desmopressin
3 Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study Unknown status NCT01439997 Phase 4 Desmopressin
4 Desmopressin for Bleeding Related to Low Body Temperature Unknown status NCT00902057 Phase 4 desmopressin;desmopressin;desmopressin;placebo
5 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
6 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
7 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4 Tolvaptan;Placebo
8 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4 tolvaptan
9 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy Completed NCT00748072 Phase 4 DDAVP;saline solution
10 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
11 Desmopressin in Cardiac Surgery Completed NCT00337766 Phase 4 Desmopressin (DDAVP);Placebo
12 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
13 Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy Completed NCT01700478 Phase 4 Misoprostol + vasopressin;Vasopressin
14 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4 Desmopressin lyophilisate (Melt)
15 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4 Tolvaptan;Hypertonic saline infusion
16 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4 Conivaptan;Placebo (Dextrose)
17 A New Check-list Method for Nocturnal Enuresis Completed NCT03510975 Phase 4 desmopressin melt form 120 μg
18 Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery Completed NCT02125188 Phase 4 Desmopressin;saline
19 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
20 Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study Completed NCT01435083 Phase 4 Desmopressin
21 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4 desmopressin tablet;desmopressin MELT formulation
22 A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis Completed NCT00245479 Phase 4 Primary nocturnal enuresis
23 A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) Completed NCT00209261 Phase 4 MINIRIN Oral Lyophilisate;Minirin tablet
24 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
25 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial Completed NCT00799292 Phase 4 Vasopressin
26 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
27 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4 Tolvaptan;Placebo of tolvaptan
28 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4 Tolvaptan
29 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4 Tolvaptan;Placebo
30 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4 Conivaptan;placebo
31 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4 loop diuretic;tolvaptan
32 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Completed NCT02183792 Phase 4 Tolvaptan;Furosemide
33 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
34 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Completed NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
35 Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults Completed NCT02822898 Phase 4 NaCl 0.9% in Glucose 5% with 40mEq Potassium;Glucion 5%
36 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4 tolvaptan
37 The Effect of Midazolam Premedication on Copeptine Concentration in Blood Recruiting NCT03474939 Phase 4 Midazolam Oral Tablet
38 The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings. Recruiting NCT03389412 Phase 4 Desmopressin
39 Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients Recruiting NCT03366857 Phase 4 Oxygen 30 %;Oxygen 80 %
40 The Effect of Propofol or Sevoflurane on Renal Function Recruiting NCT03336801 Phase 4 Propofol;Sevoflurane
41 Exercise Versus DDAVP in Patients With Mild Hemophilia A Recruiting NCT03379974 Phase 4 DDAVP Inhalant Product
42 DDAVP vs. Exercise in Patients With Mild Hemophilia A Recruiting NCT03136003 Phase 4 DDAVP
43 Combined Vaginal Misoprostol and Perivascular Vasopressin Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
44 Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Recruiting NCT03596957 Phase 4 Tolvaptan
45 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4 Tolvaptan
46 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4 Tolvaptan;Standard of care diuretic therapy
47 Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
48 Vasoactive Drugs in Intensive Care Unit Recruiting NCT02118467 Phase 4 Norepinephrine;Epinephrine;Phenylephrine;Vasopressin
49 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
50 To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors Not yet recruiting NCT03676361 Phase 4 Desmopressin

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: diabetes insipidus

Sources

Genetic Tests for Diabetes Insipidus

About this section

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29
Sources

Anatomical Context for Diabetes Insipidus

About this section

MalaCards organs/tissues related to Diabetes Insipidus:

41
Pituitary, Brain, Kidney, Testes, Thyroid, Myeloid, Lung
Sources

Publications for Diabetes Insipidus

About this section

Articles related to Diabetes Insipidus:

(show top 50) (show all 1712)
# Title Authors Year
1
Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies. ( 30207064 )
2019
2
Nephrogenic Diabetes Insipidus. ( 30454745 )
2019
3
Hemorrhagic fever with renal syndrome accompanied by panhypopituitarism and central diabetes insipidus: a case report. ( 29508304 )
2018
4
Oxcarbazepine Therapy for Complete Central Diabetes Insipidus. ( 29594147 )
2018
5
Delayed Occurrence of Diabetes Insipidus After Transsphenoidal Surgery with Radiologic Evaluation of the Pituitary Stalk on Magnetic Resonance Imaging. ( 29229338 )
2018
6
Contiguous 22.1-kb deletion embracing AVPR2 and ARHGAP4 genes at novel breakpoints leads to nephrogenic diabetes insipidus in a Chinese pedigree. ( 29394883 )
2018
7
SOCIETY FOR ENDOCRINOLOGY CLINICAL GUIDANCE: Inpatient management of cranial diabetes insipidus. ( 29930026 )
2018
8
Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus. ( 29594432 )
2018
9
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. ( 29650969 )
2018
10
Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. ( 29395172 )
2018
11
Rapid differential diagnosis of diabetes insipidus in a 7-month-old infant: The copeptin approach. ( 29241593 )
2018
12
For Debate: Personalized Health Care: As Exemplified by Home Sodium Measurements in a Child with Central Diabetes Insipidus and Impaired Thirst Perception. ( 29806747 )
2018
13
One too many diabetes: the combination of hyperglycaemic hyperosmolar state and central diabetes insipidus. ( 29675260 )
2018
14
Bartter Syndrome Type 1 Presenting as Nephrogenic Diabetes Insipidus. ( 29527380 )
2018
15
From Mechanical to Chemical: A Case of Diabetes Insipidus Induced by Concussive Brain Injury. ( 29596786 )
2018
16
Diabetes Insipidus following Endoscopic Transsphenoidal Surgery for Pituitary Adenoma. ( 29868315 )
2018
17
Systemic lupus erythematosus with SjAPgren's syndrome and renal tubular acidosis presenting as nephrogenic diabetes insipidus. ( 29657217 )
2018
18
Nephrogenic diabetes insipidus in initial stage of acute lymphoblastic leukemia and relapse after haploidentical hematopoietic stem-cell transplantation: A case report. ( 29901649 )
2018
19
Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. ( 29117938 )
2018
20
Relation between change in treatment for central diabetes insipidus and body weight loss. ( 29424204 )
2018
21
A rat model for pituitary stalk electric lesion-induced central diabetes insipidus: application of 3D printing and further outcome assessments. ( 29681579 )
2018
22
Chemical chaperone 4-phenylbutylate reduces mutant protein accumulation in the endoplasmic reticulum of arginine vasopressin neurons in a mouse model for familial neurohypophysial diabetes insipidus. ( 29886132 )
2018
23
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. ( 29141992 )
2018
24
Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats. ( 29357422 )
2018
25
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. ( 29220526 )
2018
26
Resolution of Diabetes Insipidus After Pyeloplasty: A Case Report and Review of the Literature. ( 29499256 )
2018
27
Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. ( 29716529 )
2018
28
Brain Death in Children: Incidence, Donation Rates, and the Occurrence of Central Diabetes Insipidus. ( 29967895 )
2018
29
A novel mechanism of autophagy-associated cell death of vasopressin neurons in familial neurohypophysial diabetes insipidus. ( 29961215 )
2018
30
'If there were water we should stop and drink': neurofibromatosis presenting with diabetes insipidus. ( 29440241 )
2018
31
Treatment of congenital nephrogenic diabetes insipidus in pregnancy. ( 29512817 )
2018
32
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. ( 29081004 )
2018
33
Transient diabetes insipidus in a post-partum woman with pre-eclampsia associated with residual placental vasopressinase activity. ( 29850023 )
2018
34
The Relationship Between Posterior Pituitary Bright Spot on Magnetic Resonance Imaging (MRI) and Postoperative Diabetes Insipidus for Pituitary Adenoma Patients. ( 30228254 )
2018
35
Hypothalamic relapse of a cardiac large B-cell lymphoma presenting with memory loss, confabulation, alexia-agraphia, apathy, hypersomnia, appetite disturbances and diabetes insipidus. ( 30150329 )
2018
36
Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma. ( 29984760 )
2018
37
Functional ectopic neural lobe increases GAP-43 expression via PI3K/AKT pathways to alleviate central diabetes insipidus after pituitary stalk lesion in rats. ( 29486290 )
2018
38
Nephrogenic Diabetes Insipidus in Childhood: Assessment of Volume Status and Appropriate Fluid Replenishment. ( 29489607 )
2018
39
Manifestation of Central Diabetes Insipidus in a Patient with Thyroid Storm. ( 29491282 )
2018
40
Outcome of diabetes insipidus in patients with Rathke's cleft cysts. ( 29494890 )
2018
41
A Novel Synonymous Variant in the AVP Gene Associated with Autosomal Dominant Familial Neurohypophyseal Diabetes Insipidus Causes Partial RNA Missplicing. ( 29949799 )
2018
42
A Novel Mutation in the AVPR2 Gene Causing Congenital Nephrogenic Diabetes Insipidus ( 29991464 )
2018
43
Phenotype heterogeneity of congenital adrenal hyperplasia due to genetic mosaicism and concomitant nephrogenic diabetes insipidus in a sibling. ( 29996815 )
2018
44
Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. ( 30012135 )
2018
45
A challenging coexistence of central diabetes insipidus and cerebral salt wasting syndrome: a case report. ( 30012213 )
2018
46
Soluble (Pro)Renin Receptor as a Potential Therapy for Diabetes Insipidus. ( 30019932 )
2018
47
Tamoxifen Decreases Lithium-Induced Natriuresis in Rats With Nephrogenic Diabetes Insipidus. ( 30050465 )
2018
48
Intracranial pathologies associated with central diabetes insipidus in infants. ( 30052518 )
2018
49
A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. ( 30067922 )
2018
50
Fatal Fournier's gangrene caused by Clostridium ramosum in a patient with central diabetes insipidus and insulin-dependent diabetes mellitus: a case report. ( 30071825 )
2018
Sources

Variations for Diabetes Insipidus

About this section

ClinVar genetic disease variations for Diabetes Insipidus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh38 Chromosome 20, 45304356: 45304356
2 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh37 Chromosome 20, 43932996: 43932996
Sources

Expression for Diabetes Insipidus

About this section
Search GEO for disease gene expression data for Diabetes Insipidus.
Sources

Pathways for Diabetes Insipidus

About this section

Pathways related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
12.16 AVP POMC SLC12A1 WFS1
2
Glucose / Energy Metabolism 4
12.05 AQP2 CISD2 INS WFS1
3
Peptide hormone metabolism 66
Show member pathways
 11.8 INS POMC REN
4
G alpha (s) signalling events 66
11.09 AVP AVPR2 CRH POMC
5
Diuretics Pathway, Pharmacodynamics 61
10.87 CLCNKA SLC12A1
6
Vasopressin-regulated water reabsorption 37
10.78 AQP2 AVP AVPR2
7
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10 CRH POMC
Sources

GO Terms for Diabetes Insipidus

About this section

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 AVP CRH INS POMC PRL REN
2 endosome lumen GO:0031904 8.96 INS PRL
3 secretory granule GO:0030141 8.8 AVP POMC PRL

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.78 AVP INS POMC PRL
2 positive regulation of gene expression GO:0010628 9.76 AVP AVPR2 CRH INS
3 response to ethanol GO:0045471 9.58 AVP CRH PRL
4 positive regulation of cell proliferation GO:0008284 9.55 AVP AVPR2 CRH INS PRL
5 glucose homeostasis GO:0042593 9.54 INS POMC WFS1
6 positive regulation of vasoconstriction GO:0045907 9.51 AVP AVPR2
7 response to immobilization stress GO:0035902 9.49 CRH REN
8 water transport GO:0006833 9.43 AQP2 AVP
9 parturition GO:0007567 9.32 CRH PRL
10 positive regulation of systemic arterial blood pressure GO:0003084 9.26 AVP AVPR2
11 excretion GO:0007588 9.13 AQP2 AVPR2 CLCNKA
12 renal water homeostasis GO:0003091 8.92 AQP2 AVP AVPR2 WFS1

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.46 AVP CRH POMC REN
2 neuropeptide hormone activity GO:0005184 9.26 AVP CRH
3 hormone activity GO:0005179 9.02 AVP CRH INS POMC PRL
4 insulin-like growth factor receptor binding GO:0005159 8.96 INS REN
Sources

Sources for Diabetes Insipidus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....